A Randomized Phase II Study of Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients: ESCALATE Study

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Goserelin (Primary) ; Leuprorelin (Primary) ; Triptorelin (Primary) ; Anthracyclines; Cyclophosphamide; Docetaxel; Paclitaxel
Indications Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms ESCALATE

31 Jan 2024 New trial record
28 Jan 2024 Planned initiation date changed from 15 Jan 2024 to 15 Feb 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com